ISOVUE 128 INJECTION 26 %
IOPAMIDOL : 26 % · DIN 02229005 · BRACCO IMAGING CANADA
Health Canada status: CANCELLED POST MARKET
What is ISOVUE 128 INJECTION?
ISOVUE 128 INJECTION 26 % contains IOPAMIDOL : 26 %. It is listed in the Health Canada Drug Product Database under DIN 02229005, held by BRACCO IMAGING CANADA, supplied as LIQUID for INTRAVENOUS administration. Health Canada currently lists it as cancelled post market, status dated 20-Jul-2000. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
Product details and regulatory record
| DIN | 02229005 |
|---|---|
| Brand name | ISOVUE 128 INJECTION |
| Generic / active ingredient | IOPAMIDOL : 26 % |
| Manufacturer | BRACCO IMAGING CANADA |
| Strength | 26 % |
| Dosage form | LIQUID |
| Route of administration | INTRAVENOUS |
| Schedule | Ethical |
| ATC code | V08AB04 IOPAMIDOL |
| AHFS class | 36:68.00 |
| Biosimilar | No |
| Health Canada status | CANCELLED POST MARKET |
| Status date | 20-Jul-2000 |
| Original market date | 1998-01-08 00:00:00 |
What can be used instead?
Other Canadian products sharing ATC code V08AB04 IOPAMIDOL. 5 of 15 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| ISOVUE 200 INJECTION | 41 % | SOLUTION | BRACCO IMAGING CANADA | MARKETED | DIN 02229013 |
| ISOVUE 300 INJECTION | 61 % | LIQUID | BRACCO IMAGING CANADA | MARKETED | DIN 02229021 |
| ISOVUE 370 INJECTION | 76 % | LIQUID | BRACCO IMAGING CANADA | MARKETED | DIN 02229048 |
| ISOVUE MULTIPACK-300 | 61 % | LIQUID | BRACCO IMAGING CANADA | MARKETED | DIN 02242122 |
| ISOVUE MULTIPACK-370 | 76 % | LIQUID | BRACCO IMAGING CANADA | MARKETED | DIN 02242121 |
| IOPAMIDOL INJECTION USP | 61 % | SOLUTION | HOSPIRA HEALTHCARE ULC | CANCELLED PRE MARKET | DIN 02231260 |
| IOPAMIDOL INJECTION USP | 76 % | SOLUTION | HOSPIRA HEALTHCARE ULC | CANCELLED PRE MARKET | DIN 02231261 |
| ISOVUE 128 INJ 26% | 26 % | LIQUID | SQUIBB DIAGNOSTICS, DIVISION OF BRISTOL-MYERS SQUIBB CANADA INC. | CANCELLED POST MARKET | DIN 01958011 |
| ISOVUE 200 INJ 41% | 41 % | LIQUID | SQUIBB DIAGNOSTICS, DIVISION OF BRISTOL-MYERS SQUIBB CANADA INC. | CANCELLED POST MARKET | DIN 01958003 |
| ISOVUE 300 INJ 61% | 61 % | LIQUID | SQUIBB DIAGNOSTICS, DIVISION OF BRISTOL-MYERS SQUIBB CANADA INC. | CANCELLED POST MARKET | DIN 01958976 |
Who else supplies IOPAMIDOL worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. IOPAMIDOL appears in 57 registered pack listings across 8 markets, published on 6 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.